The mill's new collection is built on three pillars: material transformation, process optimization and product longevity.

Zura Bio (ZURA) stock update: tibulizumab enters Phase 2 for HS/SSc, cash runway to 2028, and key differentiation risks.

Researchers identified GSK3α as a key checkpoint controlling stem cell identity across multiple cell types. Inhibiting it ...

ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies will air interviews with BIO-key International, Inc. (Nasdaq:BKYI), 20/20 Biolabs, Inc. (Nasdaq:AIDX), Society Pass Inc. (Nasdaq:SOPA ...

The trial will enrol up to 30 PAH and ten ILD-PH class II and III patients for ROC-101 combination therapy.

BACKGROUND: Preeclampsia affects approximately 1 in 10 pregnancies, leading to severe complications and long-term health ...

PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338, ...

Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be ...